Professor of Radiation Oncology
College of Medicine
For the past 23 years, Dietmar W. Siemann’s research has focused on the tumor microenvironment and its impact on cancer treatments.
Currently, he is developing and evaluating new ways to treat cancer by targeting the blood vessels that support the continuous growth of tumors. Unlike conventional cancer treatments, anti?vascular agents kill tumor cells by cutting off their supply of essential nutrients. These agents may also affect the central regions of the tumor that are least susceptible to other forms of treatment. Most importantly, the anti?vascular agents can be combined with radiation and chemotherapy to kill 10?500 times more tumor cells than conventional treatments alone.
Nancy Price Mendenhall, chair of the Department of Radiation Oncology, says “Dr. Siemann’s work with anti?vascular agents is not only extremely exciting from a mechanistic perspective, but also very likely to significantly impact oncologic therapy over the next decade.”
Siemann joined the Department of Radiation Oncology in 1995 to establish a translational cancer research program with close links between the clinic and the laboratory. He was recently appointed to head the Experimental Therapeutics Program of the Shands Cancer Center.
The National Cancer Institute has continuously funded Siemann’s research since 1982. He also collaborates closely with the pharmaceutical industry, which has sponsored some of his efforts in developing new anti?cancer agents. Siemann has published more than 150 articles during his career and regularly presents at national and international cancer symposia.
Siemann believes in the importance of training future scientists. He is an active participant in graduate education at the University of Florida and has trained 15 graduate students and postdoctoral fellows in his laboratory. His ultimate goal is to develop and advance new treatment strategies for the clinical management of cancer.